对BRCA-1的植入前遗传检测和降低风险的手术在35岁时比40岁更具成本效益
Kiley Hunkler1, David Boedeker1, Kelby Bulles2
1Walter Reed National Military Medical Center, Bethesda, MD.
Fertility and sterility
|February 22, 2026
概括
对于BRCA1突变携带者来说,在35岁时进行体外受精与植入前检测比延迟干预到40岁更具成本效益. 这一策略增加了活产,并减少了卵巢癌的发病率和死亡率.
科学领域:
- 生殖医学和瘤学.
- 卫生经济学和决策分析.
背景情况:
- 携带BRCA1突变的携带者面临卵巢癌和乳腺癌的风险增加.
- 预防性沙卵巢切除术是一种关键的降低风险的策略.
- 生殖欲望和癌症风险管理需要做出复杂的决定.
研究的目的:
- 为了比较早期 (35岁) 与延迟 (40岁) 的干预对BRCA1突变载体的成本效益.
- 干预措施包括体外受精 (IVF) 与单一性疾病的植入前遗传检测 (PGT) 以及降低风险的双边salpingo-oophorectomy (RRBSO).
主要方法:
- 使用马尔科夫数学模型进行了成本效益分析.
- 关于概率,成本和公用事业的数据来源于现有文献.
- 主要结果是成本效益,用增量成本效益比率 (ICER) 相对于每年质量调整后生命年 (QALY) 100,000 美元的支付意愿 (WTP) 门来衡量.
主要成果:
- 35岁的干预表明绝对主导延迟到40岁,ICER为-153.
- 35岁的策略产生了950个额外的活产,减少了726个卵巢癌病例,减少了每10,000名BRCA1携带者705例死亡.
- 将干预推迟到40岁增加了370万美元的成本,导致24379个QALY减少;概率灵敏度分析证实35岁队列在WTP值中占主导地位,最高达20万美元.
结论:
- 对于BRCA1突变携带者来说,在35岁时使用PGT进行单一性疾病的试管婴儿是具有成本效益的,而不是延迟到40岁.
- 这一策略提高了生殖结果,并显著减少了卵巢癌的负担.
- 与多学科团队共同决策对于辅导BRCA1携带者至关重要.
相关概念视频
Oogenesis
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


